Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation

Craig M Pratt; Denis Roy; Christian Torp-Pedersen; D George Wyse; Egon Toft; Steen Juul-Moller; Enrique Retyk; David Humphrey Drenning; Atrial Arrhythmia Conversion Trial (ACT-III) Investigators

doi:10.1016/j.amjcard.2010.06.054

Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation

Craig M Pratt, Denis Roy, Christian Torp-Pedersen, D George Wyse, Egon Toft, Steen Juul-Moller, Enrique Retyk, David Humphrey Drenning, Atrial Arrhythmia Conversion Trial (ACT-III) Investigators

100 Citations (Scopus)

Abstract

The objective of the present study was to assess the safety and effectiveness of vernakalant hydrochloride injection (RSD1235), a novel antiarrhythmic drug, for the conversion of atrial fibrillation (AF) or atrial flutter to sinus rhythm (SR). Patients with either AF or atrial flutter were randomized in a 1:1 ratio to receive vernakalant (n = 138) or placebo (n = 138) and were stratified by an arrhythmia duration of >3 hours to ≤7 days (short duration) and 8 to ≤45 days (long duration). The first infusion of placebo or vernakalant (3 mg/kg) was given for 10 minutes followed by a second infusion of placebo or vernakalant (2 mg/kg) 15 minutes later if the arrhythmia had not terminated. A total of 265 patients were randomized and received treatment. The primary end point was conversion of AF to SR for <1 minute within 90 minutes of the start of the drug infusion in the short-duration AF group. Of the 86 patients receiving vernakalant in the short-duration AF group, 44 (51.2%) demonstrated conversion to SR compared to 3 (3.6%) of the 84 in the placebo group (p <0.0001). The median interval to conversion of short-duration AF to SR in the responders given vernakalant was 8 minutes. Of the entire AF population (short- and long-duration AF), 47 (39.8%) of the 118 vernakalant patients experienced conversion of AF to SR compared to 4 (3.3%) of the 121 placebo patients (p <0.0001). Transient dysgeusia and sneezing were the most common adverse events in the vernakalant patients. One vernakalant patient who had severe aortic stenosis experienced hypotension and ventricular fibrillation and died. In conclusion, vernakalant demonstrated a rapid and high rate of conversion for short-duration AF and was well tolerated.

Original language	English
Journal	American Journal of Cardiology
Volume	106
Issue number	9
Pages (from-to)	1277-83
Number of pages	7
ISSN	0002-9149
DOIs	https://doi.org/10.1016/j.amjcard.2010.06.054
Publication status	Published - 1 Nov 2010

Access to Document

10.1016/j.amjcard.2010.06.054

Cite this

@article{459f967db4bf41bcbd01f9667855193c,

title = "Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation",

abstract = "The objective of the present study was to assess the safety and effectiveness of vernakalant hydrochloride injection (RSD1235), a novel antiarrhythmic drug, for the conversion of atrial fibrillation (AF) or atrial flutter to sinus rhythm (SR). Patients with either AF or atrial flutter were randomized in a 1:1 ratio to receive vernakalant (n = 138) or placebo (n = 138) and were stratified by an arrhythmia duration of >3 hours to ≤7 days (short duration) and 8 to ≤45 days (long duration). The first infusion of placebo or vernakalant (3 mg/kg) was given for 10 minutes followed by a second infusion of placebo or vernakalant (2 mg/kg) 15 minutes later if the arrhythmia had not terminated. A total of 265 patients were randomized and received treatment. The primary end point was conversion of AF to SR for <1 minute within 90 minutes of the start of the drug infusion in the short-duration AF group. Of the 86 patients receiving vernakalant in the short-duration AF group, 44 (51.2%) demonstrated conversion to SR compared to 3 (3.6%) of the 84 in the placebo group (p <0.0001). The median interval to conversion of short-duration AF to SR in the responders given vernakalant was 8 minutes. Of the entire AF population (short- and long-duration AF), 47 (39.8%) of the 118 vernakalant patients experienced conversion of AF to SR compared to 4 (3.3%) of the 121 placebo patients (p <0.0001). Transient dysgeusia and sneezing were the most common adverse events in the vernakalant patients. One vernakalant patient who had severe aortic stenosis experienced hypotension and ventricular fibrillation and died. In conclusion, vernakalant demonstrated a rapid and high rate of conversion for short-duration AF and was well tolerated.",

author = "Pratt, {Craig M} and Denis Roy and Christian Torp-Pedersen and Wyse, {D George} and Egon Toft and Steen Juul-Moller and Enrique Retyk and Drenning, {David Humphrey} and Torp-Pedersen, {Christian Tobias}",

year = "2010",

month = nov,

day = "1",

doi = "10.1016/j.amjcard.2010.06.054",

language = "English",

volume = "106",

pages = "1277--83",

journal = "Am. J. Cardiol.",

issn = "0002-9149",

publisher = "Elsevier",

number = "9",

}

TY - JOUR

T1 - Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation

AU - Pratt, Craig M

AU - Roy, Denis

AU - Torp-Pedersen, Christian

AU - Wyse, D George

AU - Toft, Egon

AU - Juul-Moller, Steen

AU - Retyk, Enrique

AU - Drenning, David Humphrey

AU - Atrial Arrhythmia Conversion Trial (ACT-III) Investigators

PY - 2010/11/1

Y1 - 2010/11/1

N2 - The objective of the present study was to assess the safety and effectiveness of vernakalant hydrochloride injection (RSD1235), a novel antiarrhythmic drug, for the conversion of atrial fibrillation (AF) or atrial flutter to sinus rhythm (SR). Patients with either AF or atrial flutter were randomized in a 1:1 ratio to receive vernakalant (n = 138) or placebo (n = 138) and were stratified by an arrhythmia duration of >3 hours to ≤7 days (short duration) and 8 to ≤45 days (long duration). The first infusion of placebo or vernakalant (3 mg/kg) was given for 10 minutes followed by a second infusion of placebo or vernakalant (2 mg/kg) 15 minutes later if the arrhythmia had not terminated. A total of 265 patients were randomized and received treatment. The primary end point was conversion of AF to SR for <1 minute within 90 minutes of the start of the drug infusion in the short-duration AF group. Of the 86 patients receiving vernakalant in the short-duration AF group, 44 (51.2%) demonstrated conversion to SR compared to 3 (3.6%) of the 84 in the placebo group (p <0.0001). The median interval to conversion of short-duration AF to SR in the responders given vernakalant was 8 minutes. Of the entire AF population (short- and long-duration AF), 47 (39.8%) of the 118 vernakalant patients experienced conversion of AF to SR compared to 4 (3.3%) of the 121 placebo patients (p <0.0001). Transient dysgeusia and sneezing were the most common adverse events in the vernakalant patients. One vernakalant patient who had severe aortic stenosis experienced hypotension and ventricular fibrillation and died. In conclusion, vernakalant demonstrated a rapid and high rate of conversion for short-duration AF and was well tolerated.

AB - The objective of the present study was to assess the safety and effectiveness of vernakalant hydrochloride injection (RSD1235), a novel antiarrhythmic drug, for the conversion of atrial fibrillation (AF) or atrial flutter to sinus rhythm (SR). Patients with either AF or atrial flutter were randomized in a 1:1 ratio to receive vernakalant (n = 138) or placebo (n = 138) and were stratified by an arrhythmia duration of >3 hours to ≤7 days (short duration) and 8 to ≤45 days (long duration). The first infusion of placebo or vernakalant (3 mg/kg) was given for 10 minutes followed by a second infusion of placebo or vernakalant (2 mg/kg) 15 minutes later if the arrhythmia had not terminated. A total of 265 patients were randomized and received treatment. The primary end point was conversion of AF to SR for <1 minute within 90 minutes of the start of the drug infusion in the short-duration AF group. Of the 86 patients receiving vernakalant in the short-duration AF group, 44 (51.2%) demonstrated conversion to SR compared to 3 (3.6%) of the 84 in the placebo group (p <0.0001). The median interval to conversion of short-duration AF to SR in the responders given vernakalant was 8 minutes. Of the entire AF population (short- and long-duration AF), 47 (39.8%) of the 118 vernakalant patients experienced conversion of AF to SR compared to 4 (3.3%) of the 121 placebo patients (p <0.0001). Transient dysgeusia and sneezing were the most common adverse events in the vernakalant patients. One vernakalant patient who had severe aortic stenosis experienced hypotension and ventricular fibrillation and died. In conclusion, vernakalant demonstrated a rapid and high rate of conversion for short-duration AF and was well tolerated.

U2 - 10.1016/j.amjcard.2010.06.054

DO - 10.1016/j.amjcard.2010.06.054

M3 - Journal article

SN - 0002-9149

VL - 106

SP - 1277

EP - 1283

JO - Am. J. Cardiol.

JF - Am. J. Cardiol.

IS - 9

ER -

Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation

Abstract

Access to Document

Fingerprint

Cite this